Panel: Navigating a Successful Licensing Deal with China

Session details:

The rhetoric toward China from some quarters may be ramping up, but the country has only become more important as a source of biotech innovation. How can Western companies balance the politics against the science, navigate differences in China’s clinical trial landscape and still pay a fair price for promising assets?